Panbio subsidiary wins US defence department grant
Thursday, 16 February, 2006
Panbio's (ASX:PBO) US subsidiary Panbio Inc has been awarded almost US$100,000 (AUD$135,000) in funding from the US Deparment of Defence.
The Phase I Small Business Innovation Research grant will fund the development of a multiplex assay for agents of infectious disease based on Panbio's patented Oligo Rapid lateral flow technology which will enable testing for multiple disease states from a single disposable device.
If Maryland-based Panbio Inc successfully completes the research for the grant, the company can bid for a Phase 2 grant, valued up to US$750,000.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
